- Home
- VPG vs AVTX Comparison
VPG vs AVTX Comparison
Compare VPG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VPG | AVTX |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.7M | 982.5M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VPG | AVTX |
|---|---|---|
| Price | $60.05 | $18.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $53.50 | $40.57 |
| AVG Volume (30 Days) | 577.4K | ★ 718.3K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $307,202,000.00 | $27,813,137.00 |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.22 | ★ 2312.27 |
| 52 Week Low | $27.74 | $9.54 |
| 52 Week High | $151.78 | $24.27 |
Technical Indicators
Market Signals| Indicator | VPG | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.63 | 49.22 |
| Support Level | $38.13 | $18.88 |
| Resistance Level | $76.58 | $20.60 |
| Average True Range (ATR) | 3.70 | 0.82 |
| MACD | 0.94 | -0.14 |
| Stochastic Oscillator | 6.20 | 33.02 |
Price Performance
Historical ComparisonAbout VPG Vishay Precision Group Inc.
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.